Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
Weijie Ma, Barbara M. Gilligan, Jianda Yuan, et al.
Journal of Hematology & Oncology (2016) Vol. 9, Iss. 1
Open Access | Times Cited: 301

Showing 1-25 of 301 citing articles:

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Andreas D. Hartkopf, Florin‐Andrei Taran, Markus Wallwiener, et al.
Breast Care (2016) Vol. 11, Iss. 6, pp. 385-390
Open Access | Times Cited: 30388
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
Min Yuan, Lili Huang, Jianhua Chen, et al.
Signal Transduction and Targeted Therapy (2019) Vol. 4, Iss. 1
Open Access | Times Cited: 602
Cancer immunotherapies targeting the PD-1 signaling pathway
Yoshiko Iwai, Junzo Hamanishi, Kenji Chamoto, et al.
Journal of Biomedical Science (2017) Vol. 24, Iss. 1
Open Access | Times Cited: 569
New and emerging targeted treatments in advanced non-small-cell lung cancer
Fred R. Hirsch, Kenichi Suda, Jacinta Wiens, et al.
The Lancet (2016) Vol. 388, Iss. 10048, pp. 1012-1024
Closed Access | Times Cited: 453
Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers
Stefano Trebeschi, Silvia Girolama Drago, Nicolai J. Birkbak, et al.
Annals of Oncology (2019) Vol. 30, Iss. 6, pp. 998-1004
Open Access | Times Cited: 451
Fates of CD8+ T cells in Tumor Microenvironment
Nomathamsanqa Resegofetse Maimela, Shasha Liu, Yi Zhang
Computational and Structural Biotechnology Journal (2018) Vol. 17, pp. 1-13
Open Access | Times Cited: 416
PD‐1/PD‐L1 immune checkpoint: Potential target for cancer therapy
Fatemeh Karimi Dermani, Pouria Samadi, Golebagh Rahmani, et al.
Journal of Cellular Physiology (2018) Vol. 234, Iss. 2, pp. 1313-1325
Closed Access | Times Cited: 413
Biological Consequences of MHC-II Expression by Tumor Cells in Cancer
Margaret L. Axelrod, Rebecca S. Cook, Douglas B. Johnson, et al.
Clinical Cancer Research (2018) Vol. 25, Iss. 8, pp. 2392-2402
Open Access | Times Cited: 372
Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)
Patrick Danaher, Sarah Warren, Rongze Lu, et al.
Journal for ImmunoTherapy of Cancer (2018) Vol. 6, Iss. 1
Open Access | Times Cited: 361
PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition
Yilun Wu, Weiyu Chen, Zhi Ping Xu, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 355
Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
Xiaolei Li, Changshun Shao, Yufang Shi, et al.
Journal of Hematology & Oncology (2018) Vol. 11, Iss. 1
Open Access | Times Cited: 321
Current Development Status of MEK Inhibitors
Ying Cheng, Hongqi Tian
Molecules (2017) Vol. 22, Iss. 10, pp. 1551-1551
Open Access | Times Cited: 241
VSIG‐3 as a ligand of VISTA inhibits human T‐cell function
Jinghua Wang, Guoping Wu, Brian Manick, et al.
Immunology (2018) Vol. 156, Iss. 1, pp. 74-85
Open Access | Times Cited: 220
PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis
Minghui Zhang, Guoliang Li, Yanbo Wang, et al.
Scientific Reports (2017) Vol. 7, Iss. 1
Open Access | Times Cited: 210
PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics
Margarita Udall, Maria L. Rizzo, Juliet Kenny, et al.
Diagnostic Pathology (2018) Vol. 13, Iss. 1
Open Access | Times Cited: 198
Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion
Yi‐Ting Wang, Huanbin Wang, Han Yao, et al.
Frontiers in Pharmacology (2018) Vol. 9
Open Access | Times Cited: 195
Development of PARP and Immune-Checkpoint Inhibitor Combinations
Ross Stewart, Patrick G. Pilié, Timothy A. Yap
Cancer Research (2018) Vol. 78, Iss. 24, pp. 6717-6725
Open Access | Times Cited: 189
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
Xin Li, Yasong Cheng, Mingzhi Zhang, et al.
Journal of Hematology & Oncology (2018) Vol. 11, Iss. 1
Open Access | Times Cited: 180
Inhibitory Receptors and Pathways of Lymphocytes: The Role of PD-1 in Treg Development and Their Involvement in Autoimmunity Onset and Cancer Progression
Elena Gianchecchi, Alessandra Fierabracci
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 180
Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies
Elisabeth Pérez-Ruíz, Ignacio Melero, Joanna Kopecka, et al.
Drug Resistance Updates (2020) Vol. 53, pp. 100718-100718
Open Access | Times Cited: 162
Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker
Bingxi He, Di Dong, Yunlang She, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 2, pp. e000550-e000550
Open Access | Times Cited: 155
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Laurence P. Diggs, Eddy C. Hsueh
Biomarker Research (2017) Vol. 5, Iss. 1
Open Access | Times Cited: 165
PD-1/PD-L1 Pathway in Breast Cancer
Florian Schütz, S Stefanović, Luisa Mayer, et al.
Oncology Research and Treatment (2017) Vol. 40, Iss. 5, pp. 294-297
Open Access | Times Cited: 162
Gut microbiome modulates efficacy of immune checkpoint inhibitors
Ming Yi, Shengnan Yu, Shuang Qin, et al.
Journal of Hematology & Oncology (2018) Vol. 11, Iss. 1
Open Access | Times Cited: 161
Is CD47 an innate immune checkpoint for tumor evasion?
Xiaojuan Liu, Hyunwoo Kwon, Zihai Li, et al.
Journal of Hematology & Oncology (2017) Vol. 10, Iss. 1
Open Access | Times Cited: 156
Page 1 - Next Page

Scroll to top